

Seattle Sperm Bank



Client/Sending Facility:  
Seattle Sperm Bank

4915 25th Ave Ne Ste 204  
SEATTLE, WA 98105  
Ph: (206)588-1484  
Fax: (206) 466-4696 WAB-55

LCLS Specimen Number: 019-129-1019-0  
Patient Name: 12689, DONOR  
Date of Birth: 11/12/1994  
Gender: M  
Patient ID:  
Lab Number: DCGWA21-251 L  
Indications: DONOR

Account Number: 46857540  
Ordering Physician: J OLLIFFE  
Specimen Type: BLOOD  
Client Reference:  
Date Collected: 01/19/2021  
Date Received: 01/20/2021  
Date Reported: 02/04/2021

Test: Chromosome, Blood, Routine

Cells Counted: 20  
Cells Analyzed: 5

Cells Karyotyped: 4  
Band Resolution: 550

CYTOGENETIC RESULT: 46,XY

INTERPRETATION: NORMAL MALE KARYOTYPE

Cytogenetic analysis of PHA stimulated cultures has revealed a MALE karyotype with an apparently normal GTW banding pattern in all cells observed.

This result does not exclude the possibility of subtle rearrangements below the resolution of cytogenetics or congenital anomalies due to other etiologies.

Seattle Sperm Bank


Client/Sending Facility:  
Seattle Sperm Bank

4915 25th Ave Ne Ste 204  
SEATTLE, WA 98105  
Ph: (206)588-1484  
Fax: (206) 466-4696 WAB-55



LCLS Specimen Number: 019-129-1019-0  
Patient Name: 12689, DONOR  
Date of Birth: 11/12/1994  
Gender: M  
Patient ID:  
Lab Number: DCGWA21-251 L

Account Number: 46857540  
Ordering Physician: J OLLIFFE  
Specimen Type: BLOOD  
Client Reference:  
Date Collected: 01/19/2021  
Date Received: 01/20/2021





**Client/Sending Facility:**  
Seattle Sperm Bank

4915 25th Ave Ne Ste 204  
SEATTLE, WA 98105  
Ph: (206)588-1484  
Fax: (206) 466-4696      WAB-55

**LCLS Specimen Number:** 019-129-1019-0  
**Patient Name:** 12689, DONOR  
**Date of Birth:** 11/12/1994  
**Gender:** M  
**Patient ID:**  
**Lab Number:** DCGWA21-251 L

**Account Number:** 46857540  
**Ordering Physician:** J OLLIFFE  
**Specimen Type:** BLOOD  
**Client Reference:**  
**Date Collected:** 01/19/2021  
**Date Received:** 01/20/2021

---

Hiba Risheg, PhD., FACMG

Daniel Toweill, MD  
Medical Director  
Stuart Schwartz, PhD  
National Director of Cytogenetics

Technical component performed by Laboratory Corporation of America Holdings,  
550 17th Ave Ste 300 , Seattle , WA , 98122-5789 (206) 861-7000

Professional Component performed by LabCorp CLIA 50D0630157, 550 17th Ave. Suite 200, Seattle WA 98122-5789. Medical Director, Daniel Toweill, MD

This document contains private and confidential health information **protected by state and federal law.**



RESULTS RECIPIENT  
**SEATTLE SPERM BANK**  
 Attn: Jeffrey Olliffe  
 4915 25th Ave NE Ste 204W  
 Seattle, WA 98105  
 Phone: (206) 588-1484  
 Fax: (206) 466-4696  
 NPI: 1306838271  
 Report Date: 02/01/2021

MALE	FEMALE
<b>DONOR 12689</b>	N/A
DOB: 11/12/1994	
Ethnicity: Mixed or Other	
Caucasian	
Sample Type: EDTA Blood	
Date of Collection: 01/19/2021	
Date Received: 01/22/2021	
Date Tested: 01/30/2021	
Barcode: 11004512733282	
Accession ID: CSLZGCJXNHJCJ4DU	
Indication: Egg or sperm donor	

# Foresight® Carrier Screen

**NEGATIVE**

## ABOUT THIS TEST

The **Myriad Foresight Carrier Screen** utilizes sequencing, maximizing coverage across all DNA regions tested, to help you learn about your chance to have a child with a genetic disease.

## RESULTS SUMMARY

Risk Details	DONOR 12689	Partner
Panel Information	Foresight Carrier Screen Universal Panel Fundamental Plus Panel Fundamental Panel <b>(175 conditions tested)</b>	N/A
<b>All conditions tested</b> A complete list of all conditions tested can be found on page 5.	<input checked="" type="checkbox"/> <b>NEGATIVE</b> No disease-causing mutations were detected.	N/A

## CLINICAL NOTES

- None

## NEXT STEPS

- If necessary, patients can discuss residual risks with their physician or a genetic counselor.



RESULTS RECIPIENT  
SEATTLE SPERM BANK  
Attn: Jeffrey Olliffe  
NPI: 1306838271  
Report Date: 02/01/2021

MALE  
DONOR 12689  
DOB: 11/12/1994  
Ethnicity: Mixed or Other  
Caucasian  
Barcode: 11004512733282

FEMALE  
N/A

## Methods and Limitations

**DONOR 12689 [Foresight Carrier Screen]:** Sequencing with copy number analysis, spinal muscular atrophy, analysis of homologous regions, and alpha thalassemia (HBA1/HBA2) sequencing with targeted copy number analysis (Assay(s): DTS v3.2).

### Sequencing with copy number analysis

High-throughput sequencing and read-depth-based copy number analysis are used to analyze the genes listed in the Conditions Tested section of the report. Except where otherwise noted, the region of interest (ROI) comprises the indicated coding regions and 20 non-coding bases flanking each region. In a minority of cases where genomic features (e.g., long homopolymers) compromise calling fidelity, the affected non-coding bases are excluded from the ROI. The ROI is sequenced to a minimum acceptable read depth, and the sequences are compared to a reference genomic sequence (Genome Reference Consortium Human Build 37 [GRCh37]/hg19). On average, 99% of all bases in the ROI are sequenced at a read depth that is greater than the minimum read depth. Sequence variants may not be detected in areas of lower sequence coverage. Insertions and deletions may not be detected as accurately as single-nucleotide variants. Select genes or regions for which pseudogenes or other regions of homology impede reliable variant detection may be assayed using alternate technology, or they may be excluded from the ROI. *CFTR* and *DMD* testing includes analysis for exon-level deletions and duplications with an average sensitivity of ~99%. Only exon-level deletions are assayed for other genes on the panel and such deletions are detected with a sensitivity of  $\geq 75\%$ . Selected founder deletions may be detected at slightly higher sensitivity. Affected exons and/or breakpoints of copy number variants are estimated from junction reads, where available, or using the positions of affected probes. Only exons known to be included in the region affected by a copy number variant are provided in the variant nomenclature. In some cases, the copy number variant may be larger or smaller than indicated. If *GJB2* is tested, large upstream deletions involving the *GJB6* and/or *CRYL1* genes that may affect the expression of *GJB2* are also analyzed.

### Spinal muscular atrophy

Targeted copy number analysis via high-throughput sequencing is used to determine the copy number of exon 7 of the *SMN1* gene. Other genetic variants may interfere with this analysis. Some individuals with two copies of *SMN1* are "silent" carriers with both *SMN1* genes on one chromosome and no copies of the gene on the other chromosome. This is more likely in individuals who have two copies of the *SMN1* gene and are positive for the g.27134T>G single-nucleotide polymorphism (SNP) (PMID: 9199562, 23788250, and 28676062), which affects the reported residual risk; Ashkenazi Jewish or Asian patients with this genotype have a high post-test likelihood of being carriers for SMA and are reported as carriers. The g.27134T>G SNP is only reported in individuals who have two copies of *SMN1*.

### Analysis of homologous regions

A combination of high-throughput sequencing, read-depth-based copy number analysis, and targeted genotyping is used to determine the number of functional gene copies and/or the presence of selected loss-of-function variants in certain genes that have homology to other genomic regions. The precise breakpoints of large deletions in these genes cannot be determined but are instead estimated from copy number analysis. Pseudogenes may interfere with this analysis, especially when many pseudogene copies are present.

If *CYP21A2* is tested, patients who have one or more additional copies of the *CYP21A2* gene and a pathogenic variant may or may not be a carrier of 21-hydroxylase deficient CAH, depending on the chromosomal location of the variants (phase). Benign *CYP21A2* gene duplications and/or triplications will only be reported in this context. Some individuals with two functional *CYP21A2* gene copies may be "silent" carriers, with two gene copies resulting from a duplication on one chromosome and a gene deletion on the other chromosome. This and other similar rare carrier states, where complementary changes exist between the chromosomes, may not be detected by the assay. Given that the true incidence of non-classic CAH is unknown, the residual carrier and reproductive risk numbers on the report are based only on the published incidence for classic CAH. However, the published prevalence of non-classic CAH is highest in individuals of Ashkenazi Jewish, Hispanic, Italian, and Yugoslav descent. Therefore, the residual and reproductive risks are likely an underestimate for CAH, especially in the aforementioned populations, as they do not account for non-classic CAH.



RESULTS RECIPIENT  
SEATTLE SPERM BANK  
Attn: Jeffrey Oilliffe  
NPI: 1306838271  
Report Date: 02/01/2021

MALE	FEMALE
DONOR 12689	N/A
DOB: 11/12/1994	
Ethnicity: Mixed or Other	
Caucasian	
Barcode: 11004512733282	

## Alpha thalassemia (HBA1/HBA2) sequencing with targeted copy number analysis

High-throughput sequencing and read-depth-based copy number analysis are used to identify sequence variation and functional gene copies within the region of interest (ROI) of *HBA1* and *HBA2*, which includes the listed exons plus 20 intronic flanking bases. In a minority of cases where genomic features (e.g., long homopolymers) compromise calling fidelity, the affected intronic bases are not included in the ROI. The ROI is sequenced to a minimum acceptable read depth, and the sequences are compared to a reference genomic sequence (Genome Reference Consortium Human Build 37 [GRCh37]/hg19). On average, 99% of all bases in the ROI are sequenced at a read depth that is greater than the minimum read depth. Sequence variants may not be detected in areas of lower sequence coverage. Insertions and deletions may not be detected as accurately as single-nucleotide variants. For large deletions or duplications in these genes, the precise breakpoints cannot be determined but are instead estimated from copy number analysis. This assay has been validated to detect up to two additional copies of each alpha globin gene. In rare instances where assay results suggest greater than two additional copies are present, this will be noted but the specific number of gene copies observed will not be provided.

Extensive sequence homology exists between *HBA1* and *HBA2*. This sequence homology can prevent certain variants from being localized to one gene over the other. In these instances, variant nomenclature will be provided for both genes. If follow-up testing is indicated for patients with the nomenclature provided for both genes, both *HBA1* and *HBA2* should be tested. Some individuals with four functional alpha globin gene copies may be "silent" carriers, with three gene copies resulting from triplication on one chromosome and a single gene deletion on the other chromosome. This and other similar rare carrier states, where complementary changes exist between the chromosomes, may not be detected by the assay.

## Interpretation of reported variants

Variants are classified according to internally defined criteria, which are compatible with the ACMG Standards and Guidelines for the Interpretation of Sequence Variants (PMID: 25741868). Variants that are considered disease-causing by Myriad Women's Health (MWH) are reported. In addition, variants that have not previously been established as a recognized cause of disease may be identified. In these cases, only variants classified as 'likely' pathogenic are reported. Likely pathogenic variants are described elsewhere in the report as 'likely to have a negative impact on gene function.' Variant pathogenicity is evaluated and classified by an assessment of the nature of the variant and reviews of reports of allele frequencies in cases and controls, functional studies, variant annotation and effect prediction, segregation studies, and other resources, where available. Exon-level duplications in the *DMD* and *CFTR* genes are assumed to be in tandem and are classified according to their predicted effect on the reading frame. Benign variants, variants of uncertain significance, and variants not directly associated with the specified disease phenotype(s) are not reported.

## Limitations

The MWH Foresight Carrier Screen is designed to detect and report germline (constitutional) alterations. Mosaic (somatic) variation may not be detected, and if it is detected, it may not be reported. If more than one variant is detected in a gene, additional studies may be necessary to determine if those variants lie on the same chromosome or different chromosomes (phase). This test is not designed to detect sex-chromosome copy number variations. If present, sex-chromosome abnormalities may significantly reduce test sensitivity for X-linked conditions. Variant interpretation and residual and reproductive risk estimations assume a normal karyotype and may be different for individuals with abnormal karyotypes. The test does not fully address all inherited forms of intellectual disability, birth defects, or heritable diseases. Furthermore, not all forms of genetic variation are detected by this assay (i.e., duplications [except in specified genes], chromosomal rearrangements, structural abnormalities, etc.). Additional testing may be appropriate for some individuals. Pseudogenes and other regions of homology may interfere with this analysis. In an unknown number of cases, other genetic variation may interfere with variant detection. Rare carrier states where complementary changes exist between the chromosomes may not be detected by the assay. Other possible sources of diagnostic error include sample mix-up, trace contamination, bone marrow transplantation, blood transfusions, and technical or analytical errors.

Detection rates are determined using published scientific literature and/or reputable databases, when available, to estimate the fraction of disease alleles, weighted by frequency, that the methodology is predicted to be able or unable to detect. Detection rates are approximate and only account for analytical sensitivity. Certain variants that have been previously described in the literature may not be reported, if there is insufficient evidence for pathogenicity. Detection rates do not account for the disease specific rates of *de novo* variation.

This test was developed, and its performance characteristics determined by, Myriad Women's Health, Inc. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA does not require this test to go through premarket review. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These results are adjunctive to the ordering physician's evaluation. CLIA Number: #05D1102604.

## Incidental Findings



RESULTS RECIPIENT  
SEATTLE SPERM BANK  
Attn: Jeffrey Olliffe  
NPI: 1306838271  
Report Date: 02/01/2021

MALE  
DONOR 12689  
DOB: 11/12/1994  
Ethnicity: Mixed or Other  
Caucasian  
Barcode: 11004512733282

FEMALE  
N/A

Unless otherwise indicated, these results and interpretations are limited to the specific disease panel(s) requested by the ordering healthcare provider. In some cases, standard data analyses may identify genetic findings beyond the region(s) of interest specified by the test, and such findings may not be reported. These findings may include genomic abnormalities with major, minor, or no, clinical significance.

If you have questions or would like more information about any of the test methods or limitations, please contact (888) 268-6795.

## Resources

**GENOME CONNECT** | <http://www.genomeconnect.org>

Patients can share their reports using research registries such as Genome Connect, an online research registry building a genetics and health knowledge base. Genome Connect provides patients, physicians, and researchers an opportunity to share genetic information to support the study of the impact of genetic variation on health conditions.

---

### SENIOR LABORATORY DIRECTOR

A handwritten signature in black ink that reads "Karla R. Bowles".

Karla R. Bowles, PhD, FACMG, CGMB

Report content approved by Karla Bowles, PhD, FACMG, CGMB on Feb 1, 2021

# Conditions Tested

- 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia - Gene:** CYP11B1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000497:1-9. **Detection Rate:** Mixed or Other Caucasian 94%.
- 6-pyruvoyl-tetrahydropterin Synthase Deficiency - Gene:** PTS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000317:1-6. **Detection Rate:** Mixed or Other Caucasian >99%.
- ABCC8-related Familial Hyperinsulinism - Gene:** ABCC8. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000352:1-39. **Detection Rate:** Mixed or Other Caucasian >99%.
- Adenosine Deaminase Deficiency - Gene:** ADA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000022:1-12. **Detection Rate:** Mixed or Other Caucasian >99%.
- Alpha Thalassemia, HBA1/HBA2-related - Genes:** HBA1, HBA2. Autosomal Recessive. Alpha thalassemia (HBA1/HBA2) sequencing with targeted copy number analysis. Exons: NM\_000517:1-3; NM\_000558:1-3. Variants (19): -(alpha)20.5, --BRIT, --MEDI, --MEDII, --SEA, --THAI or --FIL, -alpha3.7, -alpha4.2, HBA1+HBA2 deletion, Hb Constant Spring, Poly(A) AATAAA>AATA-, Poly(A) AATAAA>AATAAG, Poly(A) AATAAA>AATGAA, anti3.7, anti4.2, c.\*93A>G, c.\*94\_\*95delAA, c.\*95A>G, del HS-40. **Detection Rate:** Not calculated due to rarity of disease in this individual's reported ethnicity.
- Alpha-mannosidosis - Gene:** MAN2B1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000528:1-23. **Detection Rate:** Mixed or Other Caucasian >99%.
- Alpha-sarcoglycanopathy - Gene:** SGCA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000023:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.
- Alstrom Syndrome - Gene:** ALMS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_015120:1-23. **Detection Rate:** Mixed or Other Caucasian >99%.
- AMT-related Glycine Encephalopathy - Gene:** AMT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000481:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.
- Andermann Syndrome - Gene:** SLC12A6. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_133647:1-25. **Detection Rate:** Mixed or Other Caucasian >99%.
- Argininemia - Gene:** ARG1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000045:1-8. **Detection Rate:** Mixed or Other Caucasian 97%.
- Argininosuccinic Aciduria - Gene:** ASL. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001024943:1-16. **Detection Rate:** Mixed or Other Caucasian >99%.
- Aspartylglucosaminuria - Gene:** AGA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000027:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.
- Ataxia with Vitamin E Deficiency - Gene:** TTPA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000370:1-5. **Detection Rate:** Mixed or Other Caucasian >99%.
- Ataxia-telangiectasia - Gene:** ATM. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000051:2-63. **Detection Rate:** Mixed or Other Caucasian 98%.
- ATP7A-related Disorders - Gene:** ATP7A. X-linked Recessive. Sequencing with copy number analysis. Exons: NM\_000052:2-23. **Detection Rate:** Mixed or Other Caucasian 96%.
- Autoimmune Polyglandular Syndrome Type 1 - Gene:** AIRE. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000383:1-14. **Detection Rate:** Mixed or Other Caucasian >99%.
- Autosomal Recessive Osteopetrosis Type 1 - Gene:** TCIRG1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_006019:2-20. **Detection Rate:** Mixed or Other Caucasian >99%.
- Autosomal Recessive Polycystic Kidney Disease, PKHD1-related - Gene:** PKHD1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_138694:2-67. **Detection Rate:** Mixed or Other Caucasian >99%.
- Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay - Gene:** SACS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_014363:2-10. **Detection Rate:** Mixed or Other Caucasian 99%.
- Bardet-Biedl Syndrome, BBS1-related - Gene:** BBS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_024649:1-17. **Detection Rate:** Mixed or Other Caucasian >99%.
- Bardet-Biedl Syndrome, BBS10-related - Gene:** BBS10. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_024685:1-2. **Detection Rate:** Mixed or Other Caucasian >99%.
- Bardet-Biedl Syndrome, BBS12-related - Gene:** BBS12. Autosomal Recessive. Sequencing with copy number analysis. Exon: NM\_152618:2. **Detection Rate:** Mixed or Other Caucasian >99%.
- Bardet-Biedl Syndrome, BBS2-related - Gene:** BBS2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_031885:1-17. **Detection Rate:** Mixed or Other Caucasian >99%.
- BCS1L-related Disorders - Gene:** BCS1L. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_004328:3-9. **Detection Rate:** Mixed or Other Caucasian >99%.
- Beta-sarcoglycanopathy - Gene:** SGCB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000232:1-6. **Detection Rate:** Mixed or Other Caucasian >99%.
- Biotinidase Deficiency - Gene:** BTD. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000060:1-4. **Detection Rate:** Mixed or Other Caucasian >99%.
- Bloom Syndrome - Gene:** BLM. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000057:2-22. **Detection Rate:** Mixed or Other Caucasian >99%.
- Calpainopathy - Gene:** CAPN3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000070:1-24. **Detection Rate:** Mixed or Other Caucasian >99%.
- Canavan Disease - Gene:** ASPA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000049:1-6. **Detection Rate:** Mixed or Other Caucasian 98%.
- Carbamoylphosphate Synthetase I Deficiency - Gene:** CPS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001875:1-38. **Detection Rate:** Mixed or Other Caucasian >99%.
- Carnitine Palmitoyltransferase IA Deficiency - Gene:** CPT1A. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001876:2-19. **Detection Rate:** Mixed or Other Caucasian >99%.
- Carnitine Palmitoyltransferase II Deficiency - Gene:** CPT2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000098:1-5. **Detection Rate:** Mixed or Other Caucasian >99%.
- Cartilage-hair Hypoplasia - Gene:** RMRP. Autosomal Recessive. Sequencing with copy number analysis. Exon: NR\_003051:1. **Detection Rate:** Mixed or Other Caucasian >99%.
- Cerebrotendinous Xanthomatosis - Gene:** CYP27A1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000784:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.
- Citrullinemia Type 1 - Gene:** ASS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000050:3-16. **Detection Rate:** Mixed or Other Caucasian >99%.
- CLN3-related Neuronal Ceroid Lipofuscinosis - Gene:** CLN3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001042432:2-16. **Detection Rate:** Mixed or Other Caucasian >99%.





RESULTS RECIPIENT  
SEATTLE SPERM BANK  
Attn: Jeffrey Olliffe  
NPI: 1306838271  
Report Date: 02/01/2021

MALE  
DONOR 12689  
DOB: 11/12/1994  
Ethnicity: Mixed or Other  
Caucasian  
Barcode: 11004512733282

FEMALE  
N/A

**CLN5-related Neuronal Ceroid Lipofuscinosis - Gene:** CLN5. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_006493:1-4. **Detection Rate:** Mixed or Other Caucasian >99%.

**CLN6-related Neuronal Ceroid Lipofuscinosis - Gene:** CLN6. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_017882:1-7. **Detection Rate:** Mixed or Other Caucasian >99%.

**CLN8-related Neuronal Ceroid Lipofuscinosis - Gene:** CLN8. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_018941:2-3. **Detection Rate:** Mixed or Other Caucasian >99%.

**Cohen Syndrome - Gene:** VPS13B. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_017890:2-62. **Detection Rate:** Mixed or Other Caucasian 97%.

**COL4A3-related Alport Syndrome - Gene:** COL4A3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000091:1-52. **Detection Rate:** Mixed or Other Caucasian 97%.

**COL4A4-related Alport Syndrome - Gene:** COL4A4. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000092:2-48. **Detection Rate:** Mixed or Other Caucasian 98%.

**Combined Pituitary Hormone Deficiency, PROP1-related - Gene:** PROP1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_006261:1-3. **Detection Rate:** Mixed or Other Caucasian >99%.

**Congenital Adrenal Hyperplasia, CYP21A2-related - Gene:** CYP21A2. Autosomal Recessive. Analysis of homologous regions. **Variants (13):** CYP21A2 deletion, CYP21A2 duplication, CYP21A2 triplication, G111Vfs\*21, I173N, L308Ffs\*6, P31L, Q319\*, Q319\*+CYP21A2dup, R357W, V282L, [I237N;V238E;M240K], c.293-13C>G. **Detection Rate:** Mixed or Other Caucasian 96%.

**Congenital Disorder of Glycosylation Type Ia - Gene:** PMM2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000303:1-8. **Detection Rate:** Mixed or Other Caucasian >99%.

**Congenital Disorder of Glycosylation Type Ic - Gene:** ALG6. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_013339:2-15. **Detection Rate:** Mixed or Other Caucasian >99%.

**Congenital Disorder of Glycosylation, MPI-related - Gene:** MPI. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_002435:1-8. **Detection Rate:** Mixed or Other Caucasian >99%.

**Costeff Optic Atrophy Syndrome - Gene:** OPA3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_025136:1-2. **Detection Rate:** Mixed or Other Caucasian >99%.

**Cystic Fibrosis - Gene:** CFTR. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000492:1-27. IVS8-5T allele analysis is only reported in the presence of the R117H mutation. **Detection Rate:** Mixed or Other Caucasian >99%.

**Cystinosis - Gene:** CTNS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_004937:3-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**D-bifunctional Protein Deficiency - Gene:** HSD17B4. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000414:1-24. **Detection Rate:** Mixed or Other Caucasian 98%.

**Delta-sarcoglycanopathy - Gene:** SGCD. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000337:2-9. **Detection Rate:** Mixed or Other Caucasian 99%.

**Dihydroipoamide Dehydrogenase Deficiency - Gene:** DLD. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000108:1-14. **Detection Rate:** Mixed or Other Caucasian >99%.

**Dysferlinopathy - Gene:** DYSF. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_003494:1-55. **Detection Rate:** Mixed or Other Caucasian 98%.

**Dystrophinopathy (Including Duchenne/Becker Muscular Dystrophy) - Gene:** DMD. X-linked Recessive. Sequencing with copy number analysis. Exons: NM\_004006:1-79. **Detection Rate:** Mixed or Other Caucasian >99%.

**ERCC6-related Disorders - Gene:** ERCC6. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000124:2-21. **Detection Rate:** Mixed or Other Caucasian 99%.

**ERCC8-related Disorders - Gene:** ERCC8. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000082:1-12. **Detection Rate:** Mixed or Other Caucasian 95%.

**EVC-related Ellis-van Creveld Syndrome - Gene:** EVC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_153717:1-21. **Detection Rate:** Mixed or Other Caucasian 96%.

**EVC2-related Ellis-van Creveld Syndrome - Gene:** EVC2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_147127:1-22. **Detection Rate:** Mixed or Other Caucasian >99%.

**Fabry Disease - Gene:** GLA. X-linked Recessive. Sequencing with copy number analysis. Exons: NM\_000169:1-7. **Detection Rate:** Mixed or Other Caucasian 98%.

**Familial Dysautonomia - Gene:** ELP1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_003640:2-37. **Detection Rate:** Mixed or Other Caucasian >99%.

**Familial Mediterranean Fever - Gene:** MEFV. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000243:1-10. **Detection Rate:** Mixed or Other Caucasian >99%.

**Fanconi Anemia Complementation Group A - Gene:** FANCA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000135:1-43. **Detection Rate:** Mixed or Other Caucasian 92%.

**Fanconi Anemia, FANCC-related - Gene:** FANCC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000136:2-15. **Detection Rate:** Mixed or Other Caucasian >99%.

**FKRP-related Disorders - Gene:** FKRP. Autosomal Recessive. Sequencing with copy number analysis. Exon: NM\_024301:4. **Detection Rate:** Mixed or Other Caucasian >99%.

**FKTN-related Disorders - Gene:** FKTN. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001079802:3-11. **Detection Rate:** Mixed or Other Caucasian >99%.

**Free Sialic Acid Storage Disorders - Gene:** SLC17A5. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_012434:1-11. **Detection Rate:** Mixed or Other Caucasian 98%.

**Galactokinase Deficiency - Gene:** GALK1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000154:1-8. **Detection Rate:** Mixed or Other Caucasian >99%.

**Galactosemia - Gene:** GALT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000155:1-11. **Detection Rate:** Mixed or Other Caucasian >99%.

**Gamma-sarcoglycanopathy - Gene:** SGCG. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000231:2-8. **Detection Rate:** Mixed or Other Caucasian 88%.

**Gaucher Disease - Gene:** GBA. Autosomal Recessive. Analysis of homologous regions. **Variants (10):** D409V, D448H, IVS2+1G>A, L444P, N370S, R463C, R463H, R496H, V394L, p.L29Afs\*18. **Detection Rate:** Mixed or Other Caucasian 60%.

**GJB2-related DFNB1 Nonsyndromic Hearing Loss and Deafness - Gene:** GJB2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_004004:1-2. **Detection Rate:** Mixed or Other Caucasian >99%.

**GLB1-related Disorders - Gene:** GLB1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000404:1-16. **Detection Rate:** Mixed or Other Caucasian >99%.

**GLDC-related Glycine Encephalopathy - Gene:** GLDC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000170:1-25. **Detection Rate:** Mixed or Other Caucasian 94%.

**Glutaric Acidemia, GCDH-related - Gene:** GCDH. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000159:2-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**Glycogen Storage Disease Type Ia - Gene:** G6PC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000151:1-5. **Detection Rate:** Mixed or Other Caucasian >99%.

**Glycogen Storage Disease Type Ib - Gene:** SLC37A4. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001164277:3-11. **Detection Rate:** Mixed or Other Caucasian >99%.



RESULTS RECIPIENT  
SEATTLE SPERM BANK  
Attn: Jeffrey Olliffe  
NPI: 1306838271  
Report Date: 02/01/2021

MALE  
DONOR 12689  
DOB: 11/12/1994  
Ethnicity: Mixed or Other  
Caucasian  
Barcode: 11004512733282

FEMALE  
N/A

**Glycogen Storage Disease Type III - Gene:** AGL. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000642:2-34. **Detection Rate:** Mixed or Other Caucasian >99%.

**GNE Myopathy - Gene:** GNE. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001128227:1-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**GNPTAB-related Disorders - Gene:** GNPTAB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_024312:1-21. **Detection Rate:** Mixed or Other Caucasian >99%.

**HADHA-related Disorders - Gene:** HADHA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000182:1-20. **Detection Rate:** Mixed or Other Caucasian >99%.

**Hb Beta Chain-related Hemoglobinopathy (Including Beta Thalassemia and Sickle Cell Disease) - Gene:** HBB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000518:1-3. **Detection Rate:** Mixed or Other Caucasian >99%.

**Hereditary Fructose Intolerance - Gene:** ALDOB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000035:2-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**Herlitz Junctional Epidermolysis Bullosa, LAMB3-related - Gene:** LAMB3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000228:2-23. **Detection Rate:** Mixed or Other Caucasian >99%.

**Hexosaminidase A Deficiency (Including Tay-Sachs Disease) - Gene:** HEXA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000520:1-14. **Detection Rate:** Mixed or Other Caucasian >99%.

**HMG-CoA Lyase Deficiency - Gene:** HMGCL. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000191:1-9. **Detection Rate:** Mixed or Other Caucasian 98%.

**Holocarboxylase Synthetase Deficiency - Gene:** HLCS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000411:4-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**Homocystinuria, CBS-related - Gene:** CBS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000071:3-17. **Detection Rate:** Mixed or Other Caucasian >99%.

**Hydrolethalus Syndrome - Gene:** HYL1. Autosomal Recessive. Sequencing with copy number analysis. Exon: NM\_145014:4. **Detection Rate:** Mixed or Other Caucasian >99%.

**Hypophosphatasia - Gene:** ALPL. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000478:2-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**Isovaleric Acidemia - Gene:** IVD. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_002225:1-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**Joubert Syndrome 2 - Gene:** TMEM216. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001173990:1-5. **Detection Rate:** Mixed or Other Caucasian >99%.

**Junctional Epidermolysis Bullosa, LAMA3-related - Gene:** LAMA3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000227:1-38. **Detection Rate:** Mixed or Other Caucasian >99%.

**Junctional Epidermolysis Bullosa, LAMC2-related - Gene:** LAMC2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_005562:1-23. **Detection Rate:** Mixed or Other Caucasian >99%.

**KCNJ11-related Familial Hyperinsulinism - Gene:** KCNJ11. Autosomal Recessive. Sequencing with copy number analysis. Exon: NM\_000525:1. **Detection Rate:** Mixed or Other Caucasian >99%.

**Krabbe Disease - Gene:** GALC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000153:1-17. **Detection Rate:** Mixed or Other Caucasian >99%.

**LAMA2-related Muscular Dystrophy - Gene:** LAMA2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000426:1-43,45-65. **Detection Rate:** Mixed or Other Caucasian >99%.

**Leigh Syndrome, French-Canadian Type - Gene:** LRPPRC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_133259:1-38. **Detection Rate:** Mixed or Other Caucasian >99%.

**Lipoid Congenital Adrenal Hyperplasia - Gene:** STAR. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000349:1-7. **Detection Rate:** Mixed or Other Caucasian >99%.

**Lysosomal Acid Lipase Deficiency - Gene:** LIPA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000235:2-10. **Detection Rate:** Mixed or Other Caucasian >99%.

**Maple Syrup Urine Disease Type Ia - Gene:** BCKDHA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000709:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**Maple Syrup Urine Disease Type Ib - Gene:** BCKDHB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_183050:1-10. **Detection Rate:** Mixed or Other Caucasian >99%.

**Maple Syrup Urine Disease Type II - Gene:** DBT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001918:1-11. **Detection Rate:** Mixed or Other Caucasian 96%.

**Medium Chain Acyl-CoA Dehydrogenase Deficiency - Gene:** ACADM. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000016:1-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**Megalencephalic Leukoencephalopathy with Subcortical Cysts - Gene:** MLC1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_015166:2-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**Metachromatic Leukodystrophy - Gene:** ARSA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000487:1-8. **Detection Rate:** Mixed or Other Caucasian >99%.

**Methylmalonic Acidemia, cblA Type - Gene:** MMAA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_172250:2-7. **Detection Rate:** Mixed or Other Caucasian >99%.

**Methylmalonic Acidemia, cblB Type - Gene:** MMAB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_052845:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**Methylmalonic Aciduria and Homocystinuria, cblC Type - Gene:** MMACHC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_015506:1-4. **Detection Rate:** Mixed or Other Caucasian >99%.

**MKS1-related Disorders - Gene:** MKS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_017777:1-18. **Detection Rate:** Mixed or Other Caucasian >99%.

**Mucopolipidosis III Gamma - Gene:** GNPTG. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_032520:1-11. **Detection Rate:** Mixed or Other Caucasian >99%.

**Mucopolipidosis IV - Gene:** MCOLN1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_020533:1-14. **Detection Rate:** Mixed or Other Caucasian >99%.

**Mucopolysaccharidosis Type I - Gene:** IDUA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000203:1-14. **Detection Rate:** Mixed or Other Caucasian >99%.

**Mucopolysaccharidosis Type II - Gene:** IDS. X-linked Recessive. Sequencing with copy number analysis. Exons: NM\_000202:1-9. **Detection Rate:** Mixed or Other Caucasian 88%.

**Mucopolysaccharidosis Type IIIA - Gene:** SGSH. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000199:1-8. **Detection Rate:** Mixed or Other Caucasian >99%.

**Mucopolysaccharidosis Type IIIB - Gene:** NAGLU. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000263:1-6. **Detection Rate:** Mixed or Other Caucasian >99%.

**Mucopolysaccharidosis Type IIIC - Gene:** HGSNAT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_152419:1-18. **Detection Rate:** Mixed or Other Caucasian >99%.

**MUT-related Methylmalonic Acidemia - Gene:** MUT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000255:2-13. **Detection Rate:** Mixed or Other Caucasian >99%.

**MYO7A-related Disorders - Gene:** MYO7A. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000260:2-49. **Detection Rate:** Mixed or Other Caucasian >99%.



RESULTS RECIPIENT  
SEATTLE SPERM BANK  
Attn: Jeffrey Olliffe  
NPI: 1306838271  
Report Date: 02/01/2021

MALE  
DONOR 12689  
DOB: 11/12/1994  
Ethnicity: Mixed or Other  
Caucasian  
Barcode: 11004512733282

FEMALE  
N/A

**NEB-related Nemaline Myopathy - Gene:** NEB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001271208:3-80,117-183. **Detection Rate:** Mixed or Other Caucasian 92%.

**Nephrotic Syndrome, NPHS1-related - Gene:** NPHS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_004646:1-29. **Detection Rate:** Mixed or Other Caucasian >99%.

**Nephrotic Syndrome, NPHS2-related - Gene:** NPHS2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_014625:1-8. **Detection Rate:** Mixed or Other Caucasian >99%.

**Niemann-Pick Disease Type C1 - Gene:** NPC1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000271:1-25. **Detection Rate:** Mixed or Other Caucasian >99%.

**Niemann-Pick Disease Type C2 - Gene:** NPC2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_006432:1-5. **Detection Rate:** Mixed or Other Caucasian >99%.

**Niemann-Pick Disease, SMPD1-related - Gene:** SMPD1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000543:1-6. **Detection Rate:** Mixed or Other Caucasian >99%.

**Nijmegen Breakage Syndrome - Gene:** NBN. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_002485:1-16. **Detection Rate:** Mixed or Other Caucasian >99%.

**Ornithine Transcarbamylase Deficiency - Gene:** OTC. X-linked Recessive. Sequencing with copy number analysis. Exons: NM\_000531:1-10. **Detection Rate:** Mixed or Other Caucasian 97%.

**PCCA-related Propionic Acidemia - Gene:** PCCA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000282:1-24. **Detection Rate:** Mixed or Other Caucasian 95%.

**PCCB-related Propionic Acidemia - Gene:** PCCB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000532:1-15. **Detection Rate:** Mixed or Other Caucasian >99%.

**PCDH15-related Disorders - Gene:** PCDH15. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_033056:2-33. **Detection Rate:** Mixed or Other Caucasian 93%.

**Pendred Syndrome - Gene:** SLC26A4. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000441:2-21. **Detection Rate:** Mixed or Other Caucasian >99%.

**Peroxisome Biogenesis Disorder Type 1 - Gene:** PEX1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000466:1-24. **Detection Rate:** Mixed or Other Caucasian >99%.

**Peroxisome Biogenesis Disorder Type 3 - Gene:** PEX12. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000286:1-3. **Detection Rate:** Mixed or Other Caucasian >99%.

**Peroxisome Biogenesis Disorder Type 4 - Gene:** PEX6. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000287:1-17. **Detection Rate:** Mixed or Other Caucasian 97%.

**Peroxisome Biogenesis Disorder Type 5 - Gene:** PEX2. Autosomal Recessive. Sequencing with copy number analysis. Exon: NM\_000318:4. **Detection Rate:** Mixed or Other Caucasian >99%.

**Peroxisome Biogenesis Disorder Type 6 - Gene:** PEX10. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_153818:1-6. **Detection Rate:** Mixed or Other Caucasian >99%.

**Phenylalanine Hydroxylase Deficiency - Gene:** PAH. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000277:1-13. **Detection Rate:** Mixed or Other Caucasian >99%.

**POMGNT-related Disorders - Gene:** POMGNT1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_017739:2-22. **Detection Rate:** Mixed or Other Caucasian 96%.

**Pompe Disease - Gene:** GAA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000152:2-20. **Detection Rate:** Mixed or Other Caucasian 98%.

**PPT1-related Neuronal Ceroid Lipofuscinosis - Gene:** PPT1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000310:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**Primary Carnitine Deficiency - Gene:** SLC22A5. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_003060:1-10. **Detection Rate:** Mixed or Other Caucasian >99%.

**Primary Hyperoxaluria Type 1 - Gene:** AGXT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000030:1-11. **Detection Rate:** Mixed or Other Caucasian >99%.

**Primary Hyperoxaluria Type 2 - Gene:** GRHPR. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_012203:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**Primary Hyperoxaluria Type 3 - Gene:** HOGA1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_138413:1-7. **Detection Rate:** Mixed or Other Caucasian >99%.

**Pycnodysostosis - Gene:** CTSK. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000396:2-8. **Detection Rate:** Mixed or Other Caucasian >99%.

**Pyruvate Carboxylase Deficiency - Gene:** PC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000920:3-22. **Detection Rate:** Mixed or Other Caucasian >99%.

**Rhizomelic Chondrodysplasia Punctata Type 1 - Gene:** PEX7. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000288:1-10. **Detection Rate:** Mixed or Other Caucasian >99%.

**RTEL1-related Disorders - Gene:** RTEL1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_032957:2-35. **Detection Rate:** Mixed or Other Caucasian >99%.

**Sandhoff Disease - Gene:** HEXB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000521:1-14. **Detection Rate:** Mixed or Other Caucasian >99%.

**Short-chain Acyl-CoA Dehydrogenase Deficiency - Gene:** ACADS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000017:1-10. **Detection Rate:** Mixed or Other Caucasian >99%.

**Sjogren-Larsson Syndrome - Gene:** ALDH3A2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000382:1-10. **Detection Rate:** Mixed or Other Caucasian 96%.

**SLC26A2-related Disorders - Gene:** SLC26A2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000112:2-3. **Detection Rate:** Mixed or Other Caucasian >99%.

**Smith-Lemli-Opitz Syndrome - Gene:** DHCR7. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001360:3-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**Spastic Paraplegia Type 15 - Gene:** ZFYVE26. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_015346:2-42. **Detection Rate:** Mixed or Other Caucasian >99%.

**Spinal Muscular Atrophy - Gene:** SMN1. Autosomal Recessive. Spinal muscular atrophy. Variant (1): SMN1 copy number. **Detection Rate:** Mixed or Other Caucasian 95%.

**Spondyl thoracic Dysostosis - Gene:** MESP2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001039958:1-2. **Detection Rate:** Mixed or Other Caucasian >99%.

**TGM1-related Autosomal Recessive Congenital Ichthyosis - Gene:** TGM1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000359:2-15. **Detection Rate:** Mixed or Other Caucasian >99%.

**TPP1-related Neuronal Ceroid Lipofuscinosis - Gene:** TPP1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000391:1-13. **Detection Rate:** Mixed or Other Caucasian >99%.

**Tyrosine Hydroxylase Deficiency - Gene:** TH. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_199292:1-14. **Detection Rate:** Mixed or Other Caucasian >99%.

**Tyrosinemia Type I - Gene:** FAH. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000137:1-14. **Detection Rate:** Mixed or Other Caucasian >99%.

**Tyrosinemia Type II - Gene:** TAT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000353:2-12. **Detection Rate:** Mixed or Other Caucasian >99%.



RESULTS RECIPIENT  
SEATTLE SPERM BANK  
Attn: Jeffrey Olliffe  
NPI: 1306838271  
Report Date: 02/01/2021

MALE  
DONOR 12689  
DOB: 11/12/1994  
Ethnicity: Mixed or Other  
Caucasian  
Barcode: 11004512733282

FEMALE  
N/A

**USH1C-related Disorders - Gene:** USH1C. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_005709:1-21. **Detection Rate:** Mixed or Other Caucasian >99%.

**USH2A-related Disorders - Gene:** USH2A. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_206933:2-72. **Detection Rate:** Mixed or Other Caucasian 94%.

**Usher Syndrome Type 3 - Gene:** CLRN1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_174878:1-3. **Detection Rate:** Mixed or Other Caucasian >99%.

**Very-long-chain Acyl-CoA Dehydrogenase Deficiency - Gene:** ACADVL. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000018:1-20. **Detection Rate:** Mixed or Other Caucasian >99%.

**Wilson Disease - Gene:** ATP7B. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000053:1-21. **Detection Rate:** Mixed or Other Caucasian >99%.

**X-linked Adrenoleukodystrophy - Gene:** ABCD1. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM\_000033:1-6. **Detection Rate:** Mixed or Other Caucasian 77%.

**X-linked Alport Syndrome - Gene:** COL4A5. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM\_000495:1-51. **Detection Rate:** Mixed or Other Caucasian 95%.

**X-linked Congenital Adrenal Hypoplasia - Gene:** NR0B1. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM\_000475:1-2. **Detection Rate:** Mixed or Other Caucasian 99%.

**X-linked Juvenile Retinoschisis - Gene:** RS1. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM\_000330:1-6. **Detection Rate:** Mixed or Other Caucasian 98%.

**X-linked Myotubular Myopathy - Gene:** MTM1. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM\_000252:2-15. **Detection Rate:** Mixed or Other Caucasian 98%.

**X-linked Severe Combined Immunodeficiency - Gene:** IL2RG. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM\_000206:1-8. **Detection Rate:** Mixed or Other Caucasian >99%.

**Xeroderma Pigmentosum Group A - Gene:** XPA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000380:1-6. **Detection Rate:** Mixed or Other Caucasian >99%.

**Xeroderma Pigmentosum Group C - Gene:** XPC. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_004628:1-16. **Detection Rate:** Mixed or Other Caucasian 97%.



RESULTS RECIPIENT  
 SEATTLE SPERM BANK  
 Attn: Jeffrey Olliffe  
 NPI: 1306838271  
 Report Date: 02/01/2021

MALE  
 DONOR 12689  
 DOB: 11/12/1994  
 Ethnicity: Mixed or Other  
 Caucasian  
 Barcode: 11004512733282

FEMALE  
 N/A

## Risk Calculations

Below are the risk calculations for all conditions tested. Negative results do not rule out the possibility of being a carrier. Residual risk is an estimate of each patient's post-test likelihood of being a carrier, while the reproductive risk represents an estimated likelihood that the patients' future children could inherit each disease. These risks are inherent to all carrier-screening tests, may vary by ethnicity, are predicated on a negative family history, and are present even given a negative test result. Inaccurate reporting of ethnicity may cause errors in risk calculation. In addition, average carrier rates are estimated using incidence or prevalence data from published scientific literature and/or reputable databases, where available, and are incorporated into residual risk calculations for each population/ethnicity. When population-specific data is not available for a condition, average worldwide incidence or prevalence is used. Further, incidence and prevalence data are only collected for the specified phenotypes (which include primarily the classic or severe forms of disease) and may not include alternate or milder disease manifestations associated with the gene. Actual incidence rates, prevalence rates, and carrier rates, and therefore actual residual risks, may be higher or lower than the estimates provided. Carrier rates, incidence/prevalence, and/or residual risks are not provided for some genes with biological or heritable properties that would make these estimates inaccurate. A '+' symbol indicates a positive result. See the full clinical report for interpretation and details. The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group.

Disease	DONOR 12689 Residual Risk	Reproductive Risk
11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia	1 in 3,800	< 1 in 1,000,000
6-pyruvoyl-tetrahydropterin Synthase Deficiency	< 1 in 50,000	< 1 in 1,000,000
ABCC8-related Familial Hyperinsulinism	1 in 17,000	< 1 in 1,000,000
Adenosine Deaminase Deficiency	1 in 22,000	< 1 in 1,000,000
Alpha Thalassemia, HBA1/HBA2-related	Alpha globin status: aa/aa.	Not calculated
Alpha-mannosidosis	1 in 35,000	< 1 in 1,000,000
Alpha-sarcoglycanopathy	< 1 in 50,000	< 1 in 1,000,000
Alstrom Syndrome	< 1 in 50,000	< 1 in 1,000,000
AMT-related Glycine Encephalopathy	1 in 22,000	< 1 in 1,000,000
Andermann Syndrome	< 1 in 50,000	< 1 in 1,000,000
Argininemia	< 1 in 17,000	< 1 in 1,000,000
Argininosuccinic Aciduria	1 in 13,000	< 1 in 1,000,000
Aspartylglucosaminuria	< 1 in 50,000	< 1 in 1,000,000
Ataxia with Vitamin E Deficiency	< 1 in 50,000	< 1 in 1,000,000
Ataxia-telangiectasia	1 in 11,000	< 1 in 1,000,000
ATP7A-related Disorders	< 1 in 1,000,000	1 in 600,000
Autoimmune Polyglandular Syndrome Type 1	1 in 15,000	< 1 in 1,000,000
Autosomal Recessive Osteopetrosis Type 1	1 in 35,000	< 1 in 1,000,000
Autosomal Recessive Polycystic Kidney Disease, PKHD1-related	1 in 8,100	< 1 in 1,000,000
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay	< 1 in 44,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS1-related	1 in 32,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS10-related	1 in 42,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS12-related	< 1 in 50,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS2-related	< 1 in 50,000	< 1 in 1,000,000
BCS1L-related Disorders	< 1 in 50,000	< 1 in 1,000,000
Beta-sarcoglycanopathy	1 in 39,000	< 1 in 1,000,000
Biotinidase Deficiency	1 in 13,000	1 in 650,000
Bloom Syndrome	< 1 in 50,000	< 1 in 1,000,000
Calpainopathy	1 in 13,000	< 1 in 1,000,000
Canavan Disease	1 in 9,700	< 1 in 1,000,000
Carbamoylphosphate Synthetase I Deficiency	< 1 in 57,000	< 1 in 1,000,000
Carnitine Palmitoyltransferase IA Deficiency	< 1 in 50,000	< 1 in 1,000,000
Carnitine Palmitoyltransferase II Deficiency	1 in 25,000	< 1 in 1,000,000
Cartilage-hair Hypoplasia	< 1 in 50,000	< 1 in 1,000,000
Cerebrotendinous Xanthomatosis	1 in 11,000	< 1 in 1,000,000
Citrullinemia Type 1	1 in 14,000	< 1 in 1,000,000
CLN3-related Neuronal Ceroid Lipofuscinosis	1 in 8,600	< 1 in 1,000,000
CLN5-related Neuronal Ceroid Lipofuscinosis	< 1 in 50,000	< 1 in 1,000,000
CLN6-related Neuronal Ceroid Lipofuscinosis	1 in 43,000	< 1 in 1,000,000
CLN8-related Neuronal Ceroid Lipofuscinosis	< 1 in 50,000	< 1 in 1,000,000
Cohen Syndrome	< 1 in 15,000	< 1 in 1,000,000
COL4A3-related Alport Syndrome	1 in 6,200	< 1 in 1,000,000
COL4A4-related Alport Syndrome	1 in 12,000	< 1 in 1,000,000
Combined Pituitary Hormone Deficiency, PROP1-related	1 in 6,100	< 1 in 1,000,000
Congenital Adrenal Hyperplasia, CYP21A2-related	1 in 1,300	1 in 280,000



RESULTS RECIPIENT  
**SEATTLE SPERM BANK**  
 Attn: Jeffrey Olliffe  
 NPI: 1306838271  
 Report Date: 02/01/2021

MALE  
**DONOR 12689**  
 DOB: 11/12/1994  
 Ethnicity: Mixed or Other  
 Caucasian  
 Barcode: 11004512733282

FEMALE  
 N/A

Disease	DONOR 12689 Residual Risk	Reproductive Risk
Congenital Disorder of Glycosylation Type Ia	1 in 16,000	< 1 in 1,000,000
Congenital Disorder of Glycosylation Type Ic	< 1 in 50,000	< 1 in 1,000,000
Congenital Disorder of Glycosylation, MPI-related	< 1 in 50,000	< 1 in 1,000,000
Costeff Optic Atrophy Syndrome	< 1 in 50,000	< 1 in 1,000,000
Cystic Fibrosis	1 in 3,000	1 in 360,000
Cystinosis	1 in 22,000	< 1 in 1,000,000
D-bifunctional Protein Deficiency	1 in 9,000	< 1 in 1,000,000
Delta-sarcoglycanopathy	< 1 in 40,000	< 1 in 1,000,000
Dihydroipoamide Dehydrogenase Deficiency	< 1 in 50,000	< 1 in 1,000,000
Dysferlinopathy	1 in 11,000	< 1 in 1,000,000
Dystrophinopathy (Including Duchenne/Becker Muscular Dystrophy)	Not calculated	Not calculated
ERCC6-related Disorders	1 in 26,000	< 1 in 1,000,000
ERCC8-related Disorders	< 1 in 9,900	< 1 in 1,000,000
EVC-related Ellis-van Creveld Syndrome	1 in 7,500	< 1 in 1,000,000
EVC2-related Ellis-van Creveld Syndrome	< 1 in 50,000	< 1 in 1,000,000
Fabry Disease	< 1 in 1,000,000	1 in 80,000
Familial Dysautonomia	< 1 in 50,000	< 1 in 1,000,000
Familial Mediterranean Fever	< 1 in 50,000	< 1 in 1,000,000
Fanconi Anemia Complementation Group A	1 in 2,800	< 1 in 1,000,000
Fanconi Anemia, FANCC-related	< 1 in 50,000	< 1 in 1,000,000
FKRP-related Disorders	1 in 16,000	< 1 in 1,000,000
FKTN-related Disorders	< 1 in 50,000	< 1 in 1,000,000
Free Sialic Acid Storage Disorders	< 1 in 30,000	< 1 in 1,000,000
Galactokinase Deficiency	1 in 10,000	< 1 in 1,000,000
Galactosemia	1 in 8,600	< 1 in 1,000,000
Gamma-sarcoglycanopathy	1 in 3,000	< 1 in 1,000,000
Gaucher Disease	1 in 260	1 in 110,000
GJB2-related DFNB1 Nonsyndromic Hearing Loss and Deafness	1 in 2,500	1 in 260,000
GLB1-related Disorders	1 in 19,000	< 1 in 1,000,000
GLDC-related Glycine Encephalopathy	1 in 2,800	< 1 in 1,000,000
Glutaric Acidemia, GCDH-related	1 in 16,000	< 1 in 1,000,000
Glycogen Storage Disease Type Ia	1 in 18,000	< 1 in 1,000,000
Glycogen Storage Disease Type Ib	1 in 35,000	< 1 in 1,000,000
Glycogen Storage Disease Type III	1 in 16,000	< 1 in 1,000,000
GNE Myopathy	1 in 23,000	< 1 in 1,000,000
GNPTAB-related Disorders	1 in 32,000	< 1 in 1,000,000
HADHA-related Disorders	1 in 20,000	< 1 in 1,000,000
Hb Beta Chain-related Hemoglobinopathy (Including Beta Thalassemia and Sickle Cell Disease)	1 in 3,100	1 in 390,000
Hereditary Fructose Intolerance	1 in 7,900	< 1 in 1,000,000
Herlitz Junctional Epidermolysis Bullosa, LAMB3-related	< 1 in 50,000	< 1 in 1,000,000
Hexosaminidase A Deficiency (Including Tay-Sachs Disease)	1 in 30,000	< 1 in 1,000,000
HMG-CoA Lyase Deficiency	< 1 in 33,000	< 1 in 1,000,000
Holocarboxylase Synthetase Deficiency	1 in 15,000	< 1 in 1,000,000
Homocystinuria, CBS-related	1 in 9,400	< 1 in 1,000,000
Hydrolethalus Syndrome	< 1 in 50,000	< 1 in 1,000,000
Hypophosphatasia	1 in 27,000	< 1 in 1,000,000
Isovaleric Acidemia	1 in 32,000	< 1 in 1,000,000
Joubert Syndrome 2	< 1 in 50,000	< 1 in 1,000,000
Junctional Epidermolysis Bullosa, LAMA3-related	< 1 in 50,000	< 1 in 1,000,000
Junctional Epidermolysis Bullosa, LAMC2-related	< 1 in 50,000	< 1 in 1,000,000
KCNJ11-related Familial Hyperinsulinism	< 1 in 50,000	< 1 in 1,000,000
Krabbe Disease	1 in 14,000	< 1 in 1,000,000
LAMA2-related Muscular Dystrophy	1 in 34,000	< 1 in 1,000,000
Leigh Syndrome, French-Canadian Type	< 1 in 50,000	< 1 in 1,000,000
Lipoid Congenital Adrenal Hyperplasia	< 1 in 50,000	< 1 in 1,000,000
Lysosomal Acid Lipase Deficiency	1 in 18,000	< 1 in 1,000,000
Maple Syrup Urine Disease Type Ia	1 in 42,000	< 1 in 1,000,000
Maple Syrup Urine Disease Type Ib	1 in 39,000	< 1 in 1,000,000
Maple Syrup Urine Disease Type II	1 in 13,000	< 1 in 1,000,000
Medium Chain Acyl-CoA Dehydrogenase Deficiency	1 in 4,400	1 in 790,000
Megalencephalic Leukoencephalopathy with Subcortical Cysts	< 1 in 50,000	< 1 in 1,000,000



RESULTS RECIPIENT  
 SEATTLE SPERM BANK  
 Attn: Jeffrey Olliffe  
 NPI: 1306838271  
 Report Date: 02/01/2021

MALE  
 DONOR 12689  
 DOB: 11/12/1994  
 Ethnicity: Mixed or Other  
 Caucasian  
 Barcode: 11004512733282

FEMALE  
 N/A

Disease	DONOR 12689 Residual Risk	Reproductive Risk
Metachromatic Leukodystrophy	1 in 16,000	< 1 in 1,000,000
Methylmalonic Acidemia, cbIA Type	< 1 in 50,000	< 1 in 1,000,000
Methylmalonic Acidemia, cbIB Type	1 in 48,000	< 1 in 1,000,000
Methylmalonic Aciduria and Homocystinuria, cbIC Type	1 in 16,000	< 1 in 1,000,000
MKS1-related Disorders	< 1 in 50,000	< 1 in 1,000,000
Mucopolipidosis III Gamma	< 1 in 50,000	< 1 in 1,000,000
Mucopolipidosis IV	< 1 in 50,000	< 1 in 1,000,000
Mucopolysaccharidosis Type I	1 in 16,000	< 1 in 1,000,000
Mucopolysaccharidosis Type II	1 in 600,000	1 in 150,000
Mucopolysaccharidosis Type IIIA	1 in 12,000	< 1 in 1,000,000
Mucopolysaccharidosis Type IIIB	1 in 25,000	< 1 in 1,000,000
Mucopolysaccharidosis Type IIIC	1 in 37,000	< 1 in 1,000,000
MUT-related Methylmalonic Acidemia	1 in 26,000	< 1 in 1,000,000
MYO7A-related Disorders	1 in 15,000	< 1 in 1,000,000
NEB-related Nemaline Myopathy	1 in 1,200	1 in 400,000
Nephrotic Syndrome, NPHS1-related	< 1 in 50,000	< 1 in 1,000,000
Nephrotic Syndrome, NPHS2-related	1 in 35,000	< 1 in 1,000,000
Niemann-Pick Disease Type C1	1 in 19,000	< 1 in 1,000,000
Niemann-Pick Disease Type C2	< 1 in 50,000	< 1 in 1,000,000
Niemann-Pick Disease, SMPD1-related	1 in 25,000	< 1 in 1,000,000
Nijmegen Breakage Syndrome	1 in 15,000	< 1 in 1,000,000
Ornithine Transcarbamylase Deficiency	< 1 in 1,000,000	1 in 140,000
PCCA-related Propionic Acidemia	1 in 4,200	< 1 in 1,000,000
PCCB-related Propionic Acidemia	1 in 22,000	< 1 in 1,000,000
PCDH15-related Disorders	1 in 3,300	< 1 in 1,000,000
Pendred Syndrome	1 in 8,200	< 1 in 1,000,000
Peroxisome Biogenesis Disorder Type 1	1 in 16,000	< 1 in 1,000,000
Peroxisome Biogenesis Disorder Type 3	1 in 44,000	< 1 in 1,000,000
Peroxisome Biogenesis Disorder Type 4	1 in 9,300	< 1 in 1,000,000
Peroxisome Biogenesis Disorder Type 5	< 1 in 71,000	< 1 in 1,000,000
Peroxisome Biogenesis Disorder Type 6	< 1 in 50,000	< 1 in 1,000,000
Phenylalanine Hydroxylase Deficiency	1 in 4,800	1 in 940,000
POMGNT-related Disorders	< 1 in 12,000	< 1 in 1,000,000
Pompe Disease	1 in 4,000	< 1 in 1,000,000
PPT1-related Neuronal Ceroid Lipofuscinosis	1 in 7,700	< 1 in 1,000,000
Primary Carnitine Deficiency	1 in 11,000	< 1 in 1,000,000
Primary Hyperoxaluria Type 1	1 in 17,000	< 1 in 1,000,000
Primary Hyperoxaluria Type 2	< 1 in 50,000	< 1 in 1,000,000
Primary Hyperoxaluria Type 3	1 in 13,000	< 1 in 1,000,000
Pycnodysostosis	1 in 43,000	< 1 in 1,000,000
Pyruvate Carboxylase Deficiency	1 in 25,000	< 1 in 1,000,000
Rhizomelic Chondrodysplasia Punctata Type 1	1 in 16,000	< 1 in 1,000,000
RTEL1-related Disorders	< 1 in 50,000	< 1 in 1,000,000
Sandhoff Disease	1 in 32,000	< 1 in 1,000,000
Short-chain Acyl-CoA Dehydrogenase Deficiency	1 in 11,000	< 1 in 1,000,000
Sjogren-Larsson Syndrome	< 1 in 12,000	< 1 in 1,000,000
SLC26A2-related Disorders	1 in 16,000	< 1 in 1,000,000
Smith-Lemli-Opitz Syndrome	1 in 9,400	< 1 in 1,000,000
Spastic Paraplegia Type 15	< 1 in 50,000	< 1 in 1,000,000
Spinal Muscular Atrophy	SMN1: 3+ copies 1 in 4,800	1 in 670,000
Spondylothoracic Dysostosis	< 1 in 50,000	< 1 in 1,000,000
TGM1-related Autosomal Recessive Congenital Ichthyosis	1 in 22,000	< 1 in 1,000,000
TPP1-related Neuronal Ceroid Lipofuscinosis	1 in 30,000	< 1 in 1,000,000
Tyrosine Hydroxylase Deficiency	< 1 in 50,000	< 1 in 1,000,000
Tyrosinemia Type I	1 in 16,000	< 1 in 1,000,000
Tyrosinemia Type II	1 in 25,000	< 1 in 1,000,000
USH1C-related Disorders	1 in 35,000	< 1 in 1,000,000
USH2A-related Disorders	1 in 2,200	< 1 in 1,000,000
Usher Syndrome Type 3	1 in 41,000	< 1 in 1,000,000
Very-long-chain Acyl-CoA Dehydrogenase Deficiency	1 in 18,000	< 1 in 1,000,000
Wilson Disease	1 in 6,500	< 1 in 1,000,000



RESULTS RECIPIENT  
 SEATTLE SPERM BANK  
 Attn: Jeffrey Olliffe  
 NPI: 1306838271  
 Report Date: 02/01/2021

MALE  
 DONOR 12689  
 DOB: 11/12/1994  
 Ethnicity: Mixed or Other  
 Caucasian  
 Barcode: 11004512733282

FEMALE  
 N/A

**Disease**

- X-linked Adrenoleukodystrophy
- X-linked Alport Syndrome
- X-linked Congenital Adrenal Hypoplasia
- X-linked Juvenile Retinoschisis
- X-linked Myotubular Myopathy
- X-linked Severe Combined Immunodeficiency
- Xeroderma Pigmentosum Group A
- Xeroderma Pigmentosum Group C

**DONOR 12689  
 Residual Risk**

- 1 in 90,000
- Not calculated
- < 1 in 1,000,000
- < 1 in 1,000,000
- Not calculated
- < 1 in 1,000,000
- < 1 in 50,000
- 1 in 7,300

**Reproductive Risk**

- 1 in 42,000
- Not calculated
- < 1 in 1,000,000
- 1 in 40,000
- Not calculated
- 1 in 200,000
- < 1 in 1,000,000
- < 1 in 1,000,000



**Patient Information**

Name: Donor 12689  
 Date of Birth: [REDACTED]  
 Sema4 ID: [REDACTED]  
 Client ID: [REDACTED]  
 Indication: Carrier Screening

**Specimen Information**

Specimen Type: Blood  
 Date Collected: 02/11/2022  
 Date Received: 02/12/2022  
 Final Report: 12/16/2022

**Referring Provider**

Jeffrey Olliffe, M.D.  
 Seattle Sperm Bank  
 4915 25th Avenue NE Suite 204W  
 Seattle, WA, 98105  
 Fax: 206-466-4696

**Unmask Additional Gene(s) (3 genes)**  
 with Personalized Residual Risk

**SUMMARY OF RESULTS AND RECOMMENDATIONS**

⊕ Positive	⊖ Negative
<p><b>Carrier of <i>WNT10A</i>-Related Ectodermal Dysplasia (AR)</b>            Associated gene(s): <i>WNT10A</i>            Variant(s) Detected: c.682T&gt;A, p.F228I, Pathogenic,            Heterozygous (one copy)</p>	<p><b>Negative for all other genes tested: <i>CFTR</i>, and <i>EYS</i></b>            To view a full list of genes and diseases tested            please see Table 1 in this report</p>

*AR=Autosomal recessive; XL=X-linked*

**Special Notes**

*Please note unmasking of CFTR intron 9 poly T alleles was unsuccessful and results are not included in this analysis.*

**Recommendations**

- Testing the partner for the above positive disorder(s) and genetic counseling are recommended.
- Consideration of residual risk by ethnicity after a negative carrier screen is recommended for the other diseases on the panel, especially in the case of a positive family history for a specific disorder. Please note that residual risks for X-linked diseases (including full repeat expansions for Fragile X syndrome) may not be accurate for males and the actual residual risk is likely to be lower.
- As genetic technologies may improve and variant classifications may change over time, it is recommended to obtain a new carrier screening test or reanalysis when a new pregnancy is being considered.

## Interpretation of positive results

### ***WNT10A*-Related Ectodermal Dysplasia (AR)**

#### **Results and Interpretation**

A heterozygous (one copy) pathogenic missense variant, c.682T>A, p.F228I, was detected in the *WNT10A* gene (NM\_025216.2). Please note that this variant has been associated with reduced penetrance and variable expressivity, and therefore some individuals with a pathogenic variant on the opposite allele may not exhibit any clinical symptoms (PMID:19559398). Individuals with the p.F228I variant in homozygosity or compound heterozygosity have been reported to exhibit highly variable phenotypes, with most symptomatic patients described as having isolated tooth agenesis, and a smaller fraction also exhibiting one or more additional ectodermal-related symptoms including nail dysplasia, fragile and/or sparse hair, hypohidrosis and dry skin or eczema (PMID: 34228861, 34593752, 33383702, 30046887, 28976000, 23401279, 20979233). An analysis of the reported literature suggested that of the symptomatic homozygotes reported, the majority have isolated tooth agenesis, and up to 25% may exhibit additional ectodermal features. When this variant is observed in compound heterozygosity with a second variant, up to 15% of patients that display any symptoms may exhibit features of the more severe clinical syndromes odonto-onycho-dermal dysplasia or Schopf-Schulz-Passarge syndrome. However, individuals with the same genotype, even within the same family, may display milder symptoms or be asymptomatic (PMID: 19559398, 22581971). Please note that individuals who harbor this variant are 2-3 times more likely than individuals in the general population to have hypodontia (PMID: 29364747). When this variant is present in trans with a pathogenic variant, it is considered to be causative for *WNT10A*-related ectodermal dysplasia. Therefore, this individual is expected to be at least a carrier for *WNT10A*-related ectodermal dysplasia. Approximately half of individuals with a heterozygous *WNT10A* variant have been reported to exhibit minor disease-associated symptoms, including abnormalities of several permanent teeth, dry skin, and sparse scalp hair, eyelashes, and/or eyebrows.

#### **What is *WNT10A*-Related Ectodermal Dysplasia?**

*WNT10A*-related ectodermal dysplasia represents a group of related conditions characterized by differences in the development of skin, hair, nails, teeth and sweat glands. Patients with *WNT10A*-related ectodermal dysplasia may exhibit a broad spectrum of symptoms affecting one or more of these tissue types with variable severity. The spectrum may range from isolated (nonsyndromic) findings affecting just one tissue type, through milder syndromic phenotypes to comparatively more severe syndromic phenotypes affecting multiple tissue types including odonto-onycho-dermal dysplasia and Schopf-Schulz-Passarge syndrome.

- Nonsyndromic tooth agenesis is characterized by the absence of one or more teeth without other significant symptoms of ectodermal dysplasia. Missing less than 6 teeth is called hypodontia whereas agenesis of 6 or more teeth is called oligodontia.
- Odonto-onycho-dermal dysplasia (OODD) is characterized by thickening of the skin on the palms of the hand and soles of the feet, and misshapen or missing nails and teeth. Some patients may have dry, thin hair and sparse eyebrows, and may have a smooth tongue with missing taste buds.
- Schopf-Schulz-Passarge syndrome (SSPS) is characterized by missing teeth and cysts at the corners of the eyes, misshapen nails or nails that separate from the nailbed, and an increased risk of basal cell and squamous cell carcinomas.

It is not possible to predict which phenotype a patient may have based on the genotype. In many cases the same genotypes have been found in patients with different clinical presentations, even among patients from the same family. Lifespan has not been reported to be shortened.

## Test description

This patient was tested for the genes listed above using one or more of the following methodologies: target capture and short-read sequencing, long-range PCR followed by short-read sequencing, targeted genotyping, and/or copy number analysis. Please note that negative results reduce but do not eliminate the possibility that this individual is a carrier for one or more of the disorders tested. Please see Table 1 for a list of genes and diseases tested with the patient's personalized residual risk. If personalized residual risk is not provided, please see the complete residual risk table at [go.sema4.com/residualrisk](http://go.sema4.com/residualrisk). Only known pathogenic or likely pathogenic variants are reported. This carrier screening test does not report likely benign variants and variants of uncertain significance (VUS). If reporting of likely benign variants and VUS are desired in this patient, please contact the laboratory at 800-298-6470, option 2 to request an amended report.



**Ruth Kornreich, Ph.D., FACMG, Laboratory Director**

## Genes and diseases tested

The personalized residual risks listed below are specific to this individual. The complete residual risk table is available at [go.sema4.com/residualrisk](https://go.sema4.com/residualrisk)

**Table 1: List of genes and diseases tested with detailed results**

Disease	Gene	Inheritance Pattern	Status	Detailed Summary
<b>Positive</b>				
<b>WNT10A-Related Ectodermal Dysplasia</b>	<i>WNT10A</i>	AR	Carrier	c.682T>A, p.F228I, Pathogenic, Heterozygous (one copy)
<b>Negative</b>				
<b>Cystic Fibrosis</b>	<i>CFTR</i>	AR	Reduced Risk	<b>Personalized Residual Risk:</b> 1 in 440
<b>Retinitis Pigmentosa 25</b>	<i>EYS</i>	AR	Reduced Risk	<b>Personalized Residual Risk:</b> 1 in 1,800

AR=Autosomal recessive; XL=X-linked

## Test methods and comments

Genomic DNA isolated from this patient was analyzed by one or more of the following methodologies, as applicable:

### Fragile X CGG Repeat Analysis (Analytical Detection Rate >99%)

PCR amplification using Asuragen, Inc. AmplideX<sup>®</sup> *FMR1* PCR reagents followed by capillary electrophoresis for allele sizing was performed. Samples positive for *FMR1* premutations and full mutations greater than 90 CGG repeats in length were further analyzed by Southern blot analysis or methylation PCR to assess the size and methylation status of the *FMR1* CGG repeat. Additional testing to determine the status of AGG interruptions within the *FMR1* CGG repeat will be automatically performed for premutation alleles ranging from 55 to 90 repeats. These results, which may modify risk for expansion, will follow in a separate report.

### Genotyping (Analytical Detection Rate >99%)

Multiplex PCR amplification and single-base pair probe extension analyses using the Agena Bioscience iPLEX Pro chemistry on a MassARRAY<sup>®</sup> System were used to identify certain recurrent variants that are complex in nature or are present in low copy repeats. Rare sequence variants may interfere with assay performance.

### Multiplex Ligation-Dependent Probe Amplification (MLPA) (Analytical Detection Rate >99%)

Conventional MLPA and/or digitalMLPA<sup>®</sup> probe sets and reagents from MRC-Holland were used for copy number variations (CNVs) analysis of specific targets versus known control samples. digitalMLPA<sup>®</sup> is a semi-quantitative technique, based on the well-established conventional MLPA method, followed by Illumina based sequencing to determine read number for amplicon quantification. False positive or negative results may occur due to rare sequence variants in target regions detected by conventional MLPA or digitalMLPA<sup>®</sup> probes. Analytical sensitivity and specificity of both the conventional MLPA method and the digitalMLPA<sup>®</sup> method are greater than 99%.

For alpha thalassemia, the copy numbers of the *HBA1* and *HBA2* genes were analyzed. Alpha-globin gene deletions, duplications, and the Constant Spring (CS) mutation are assessed. This test is expected to detect approximately 90% of all alpha-thalassemia mutations, varying by ethnicity. Carriers of alpha-thalassemia with three or more *HBA* copies on one chromosome, and one or no copies on the other chromosome, may not be precisely specified without phase analysis. With the exception of duplications, other benign alpha-globin gene polymorphisms will not be reported. Analyses of *HBA1* and *HBA2* are performed in association with long-range PCR of the coding regions followed by short-read sequencing.

For Duchenne muscular dystrophy, the copy numbers of all *DMD* exons were analyzed. Potentially pathogenic single exon deletions and duplications are confirmed by a second method. Analysis of *DMD* is performed in association with sequencing of the coding regions.

For congenital adrenal hyperplasia, the copy number of the *CYP21A2* gene was analyzed. This analysis can detect large deletions typically due to unequal meiotic crossing-over between *CYP21A2* and the pseudogene *CYP21A1P*. Classic 30-kb deletions make up approximately 20% of *CYP21A2* pathogenic alleles. This test may also identify certain point mutations in *CYP21A2* caused by gene conversion events between

*CYP21A2* and *CYP21A1P*. Some carriers may not be identified by dosage sensitive methods as this testing cannot detect individuals with two copies (duplication) of the *CYP21A2* gene on one chromosome and loss of *CYP21A2* (deletion) on the other chromosome. Analysis of *CYP21A2* is performed in association with long-range PCR of the coding regions followed by short-read sequencing.

For spinal muscular atrophy (SMA), the copy numbers of the *SMN1* and *SMN2* genes were analyzed. The individual dosage of exons 7 and 8 as well as the combined dosage of exons 1, 4, 6 and 8 of *SMN1* and *SMN2* were assessed. Copy number gains and losses can be detected. Depending on ethnicity, 6 - 29 % of carriers will not be identified by dosage sensitive methods as this testing cannot distinguish individuals with two copies (duplication) of the *SMN1* gene on one chromosome and loss of *SMN1* (deletion) on the other chromosome (silent 2+0 carrier) or identify intragenic mutation in *SMN1*. Please also note that 2% of individuals diagnosed with SMA have a causative *SMN1* variant that occurred de novo, therefore cannot be picked up by carrier screening in the parents. Analysis of *SMN1* is performed in association with short-read sequencing of exons 2a-7, followed by confirmation using long-range PCR (described below).

In individuals with two copies of *SMN1* with Ashkenazi Jewish, East Asian, African American, Native American or Caucasian ancestry, the presence or absence of c.3+80T>G significantly increases or decreases, respectively, the likelihood of being a silent 2+0 silent carrier.

MLPA for Gaucher disease (*GBA*), cystic fibrosis (*CFTR*), and non-syndromic hearing loss (*GJB2/GJB6*) will only be performed if indicated for confirmation of detected CNVs. If *GBA* analysis was performed, the copy numbers of exons 1, 3, 4, and 6 - 10 of the *GBA* gene (of 11 exons total) were analyzed. If *CFTR* analysis was performed, the copy numbers of all 27 *CFTR* exons were analyzed. If *GJB2/GJB6* analysis was performed, the copy number of the two *GJB2* exons were analyzed, as well as the presence or absence of the two upstream deletions of the *GJB2* regulatory region, del(*GJB6*-D13S1830) and del(*GJB6*-D13S1854).

#### Next Generation Sequencing (NGS) (Analytical Detection Rate >95%)

NGS was performed on a panel of genes for the purpose of identifying pathogenic or likely pathogenic variants.

Agilent SureSelect<sup>TM</sup>XT Low Input technology was used with a custom capture library to target the exonic regions and intron/exon splice junctions of the relevant genes, as well as a number of UTR, intronic or promoter regions that contain previously reported mutations. Libraries were pooled and sequenced on the Illumina NovaSeq 6000 platform, using paired-end 100 bp reads. The sequencing data was analyzed using a custom bioinformatics algorithm designed and validated in house.

The coding exons and splice junctions of the known protein-coding RefSeq genes were assessed for the average depth of coverage (minimum of 20X) and data quality threshold values. Most exons not meeting a minimum of >20X read depth across the exon are further analyzed by Sanger sequencing. Please note that several genomic regions present difficulties in mapping or obtaining read depth >20X. These regions, which are described below, will not be reflexed to Sanger sequencing if the mapping quality or coverage is poor. Any variants identified during testing in these regions are confirmed by a second method and reported if determined to be pathogenic or likely pathogenic. However, as there is a possibility of false negative results within these regions, detection rates and residual risks for these genes have been calculated with the presumption that variants in these exons will not be detected, unless included in the MassARRAY<sup>®</sup> genotyping platform.

**Exceptions:** *ABCD1* (NM\_000033.3) exons 8 and 9; *ACADSB* (NM\_001609.3) chr10:124,810,695-124,810,707 (partial exon 9); *ADA* (NM\_000022.2) exon 1; *ADAMTS2* (NM\_014244.4) exon 1; *AGPS* (NM\_003659.3) chr2:178,257,512-178,257,649 (partial exon 1); *ALDH7A1* (NM\_001182.4) chr5:125,911,150-125,911,163 (partial exon 7) and chr5:125,896,807-125,896,821 (partial exon 10); *ALMS1* (NM\_015120.4) chr2:73,612,990-73,613,041 (partial exon 1); *APOPT1* (NM\_032374.4) chr14:104,040,437-104,040,455 (partial exon 3); *CDAN1* (NM\_138477.2) exon 2; *CEP152* (NM\_014985.3) chr15:49,061,146-49,061,165 (partial exon 14) and exon 22; *CEP290* (NM\_025114.3) exon 5, exon 7, chr12:88,519,017-88,519,039 (partial exon 13), chr12:88,514,049-88,514,058 (partial exon 15), chr12:88,502,837-88,502,841 (partial exon 23), chr12:88,481,551-88,481,589 (partial exon 32), chr12:88,471,605-88,471,700 (partial exon 40); *CFTR* (NM\_000492.3) exon 10; *COL4A4* (NM\_000092.4) chr2:227,942,604-227,942,619 (partial exon 25); *COX10* (NM\_001303.3) exon 6; *CYP11B1* (NM\_000497.3) exons 3-7; *CYP11B2* (NM\_000498.3) exons 3-7; *DNAI2* (NM\_023036.4) chr17:72,308,136-72,308,147 (partial exon 12); *DOK7* (NM\_173660.4) chr4:3,465,131-3,465,161 (partial exon 1) and exon 2; *DUOX2* (NM\_014080.4) exons 6-8; *EIF2AK3* (NM\_004836.5) exon 8; *EVC* (NM\_153717.2) exon 1; *F5* (NM\_000130.4) chr1:169,551,662-169,551,679 (partial exon 2); *FH* (NM\_000143.3) exon 1; *GAMT* (NM\_000156.5) exon 1; *GLDC* (NM\_000170.2) exon 1; *GNPTAB* (NM\_024312.4) chr17:4,837,000-4,837,400 (partial exon 2); *GNPTG* (NM\_032520.4) exon 1; *GHR* (NM\_000163.4) exon 3; *GYS2* (NM\_021957.3) chr12:21,699,370-21,699,409 (partial exon 12); *HGSNAT* (NM\_152419.2) exon 1; *IDS* (NM\_000202.6) exon 3; *ITGB4* (NM\_000213.4) chr17:73,749,976-73,750,060 (partial exon 33); *JAK3* (NM\_000215.3) chr19:17,950,462-17,950,483 (partial exon 10); *LIFR* (NM\_002310.5) exon 19; *LMBRD1* (NM\_018368.3) chr6:70,459,226-70,459,257 (partial exon 5), chr6:70,447,828-70,447,836 (partial exon 7) and exon 12; *LYST* (NM\_000081.3) chr1:235,944,158-235,944,176 (partial exon 16) and chr1:235,875,350-235,875,362 (partial exon 43); *MLYCD* (NM\_012213.2) chr16:83,933,242-83,933,282 (partial exon 1); *MTR* (NM\_000254.2) chr1:237,024,418-237,024,439 (partial exon 20) and chr1:237,038,019-237,038,029 (partial exon 24); *NBEAL2* (NM\_015175.2) chr3:47,021,385-47,021,407 (partial exon 1); *NEB* (NM\_001271208.1) exons 82-105; *NPC1* (NM\_000271.4) chr18:21,123,519-21,123,538 (partial exon 14); *NPHP1* (NM\_000272.3) chr2:110,937,251-110,937,263 (partial exon 3); *OCRL* (NM\_000276.3) chrX:128,674,450-128,674,460 (partial exon 1); *PHKB* (NM\_000293.2) exon 1 and chr16:47,732,498-47,732,504 (partial exon 30); *PIGN* (NM\_176787.4) chr18:59,815,547-59,815,576 (partial exon 8); *PIP5K1C* (NM\_012398.2) exon 1 and chr19:3637602-3637616 (partial exon 17); *POU1F1* (NM\_000306.3) exon 5; *PTPRC* (NM\_002838.4) exons 11 and 23; *PUS1* (NM\_025215.5) chr12:132,414,446-132,414,532 (partial exon 2); *RPGRIP1L* (NM\_015272.2) exon

23; *SGSH* (NM\_000199.3) chr17:78,194,022-78,194,072 (partial exon 1); *SLC6A8* (NM\_005629.3) exons 3 and 4; *ST3GAL5* (NM\_003896.3) exon 1; *SURF1* (NM\_003172.3) chr9:136,223,269-136,223,307 (partial exon 1); *TRPM6* (NM\_017662.4) chr9:77,362,800-77,362,811 (partial exon 31); *TSEN54* (NM\_207346.2) exon 1; *TYR* (NM\_000372.4) exon 5; *VWF* (NM\_000552.3) exons 24-26, chr12:6,125,675-6,125,684 (partial exon 30), chr12:6,121,244-6,121,265 (partial exon 33), and exon 34.

This test will detect variants within the exons and the intron-exon boundaries of the target regions. Variants outside these regions may not be detected, including, but not limited to, UTRs, promoters, and deep intronic areas, or regions that fall into the Exceptions mentioned above. This technology may not detect all small insertion/deletions and is not diagnostic for repeat expansions and structural genomic variation. In addition, a mutation(s) in a gene not included on the panel could be present in this patient.

Variant interpretation and classification was performed based on the American College of Medical Genetics Standards and Guidelines for the Interpretation of Sequence Variants (Richards et al, 2015). All potentially pathogenic variants may be confirmed by either a specific genotyping assay or Sanger sequencing, if indicated. Any benign variants, likely benign variants or variants of uncertain significance identified during this analysis will not be reported.

#### Next Generation Sequencing for *SMN1*

Exonic regions and intron/exon splice junctions of *SMN1* and *SMN2* were captured, sequenced, and analyzed as described above. Any variants located within exons 2a-7 and classified as pathogenic or likely pathogenic were confirmed to be in either *SMN1* or *SMN2* using gene-specific long-range PCR analysis followed by Sanger sequencing. Variants located in exon 1 cannot be accurately assigned to either *SMN1* or *SMN2* using our current methodology, and so these variants are not reported.

#### Copy Number Variant (CNV) Analysis (Analytical Detection Rate >98% for CNVs of 3 exons and larger, >90% for CNVs of 2 exons)

Large duplications and deletions were called from the relative read depths on an exon-by-exon basis using a custom exome hidden Markov model (XHMM) algorithm. Deletions or duplications determined to be pathogenic or likely pathogenic were confirmed by either a custom arrayCGH platform, quantitative PCR, or MLPA (depending on CNV size and gene content). While this algorithm is designed to pick up deletions and duplications of 2 or more exons in length, potentially pathogenic single-exon CNVs will be confirmed and reported, if detected. Deletions and duplications near the lower limit of detection may not be detected due to run variability. Genomic regions with high homology or highly repetitive sequences are excluded from this analysis.

#### Exon Array Comparative Genomic Hybridization (aCGH) (Confirmation method) (Accuracy >99%)

The customized oligonucleotide microarray (Oxford Gene Technology) is a highly-targeted exon-focused array capable of detecting medically relevant microdeletions and microduplications at a much higher resolution than traditional aCGH methods. Each array matrix has approximately 1,000,000 60-mer oligonucleotide probes that cover the entire genome. This platform is designed based on human genome NCBI Build 37 (hg19) and the CGH probes are enriched to target the exonic regions of the genes in this panel.

#### Quantitative PCR (Confirmation method) (Accuracy >99%)

The relative quantification PCR is utilized on a Roche SYBR Green reagents on a LightCycler<sup>®</sup> 480 System, which relates the PCR signal of the target region in one group to another. To test for genomic imbalances, both sample DNA and reference DNA is amplified with primer/probe sets that specific to the target region and a control region with known genomic copy number. Relative genomic copy numbers are calculated based on the standard  $\Delta\Delta C_t$  formula.

#### Long-Range PCR (Analytical Detection Rate >99%)

Long-range PCR was performed to generate locus-specific amplicons for *CYP21A2*, *HBA1* and *HBA2* and *GBA*. The PCR products were then prepared for short-read NGS sequencing and sequenced. Sequenced reads were mapped back to the original genomic locus and run through the bioinformatics pipeline. If indicated, copy number from MLPA was correlated with the sequencing output to analyze the results. Please note that in rare cases, allele drop-out may occur, which has the potential to lead to false negative results. For *CYP21A2*, a certain percentage of healthy individuals carry a duplication of the *CYP21A2* gene, which has no clinical consequences. In cases where multiple copies of *CYP21A2* are located on the same chromosome in tandem, only the last copy will be amplified and assessed for potentially pathogenic variants, due to size limitations of the PCR reaction. However, because these alleles contain at least two copies of the *CYP21A2* gene in tandem, it is expected that this patient has at least one functional gene in the tandem allele and this patient is therefore less likely to be a carrier. A *CYP21A1P/CYP21A2* hybrid gene detected only by MLPA but not by long-range PCR will not be reported when the long-range PCR indicates the presence of two full *CYP21A2* gene copies (one on each chromosome), as the additional hybrid gene is nonfunctional. Classic 30-kb deletions are identified by MLPA and are also identified by the presence of multiple common pathogenic *CYP21A2* variants by long-range PCR. Since multiple pseudogene-derived variants are detected in all cases with the classic 30kb deletion, we cannot rule out the possibility that some variant(s) detected could be present in trans with the chimeric *CYP21A1P/CYP21A2* gene created by the 30kb deletion. When an individual carries both a duplication allele and a pathogenic variant, or multiple pathogenic variants, the current analysis may not be able to determine

the phase (cis/trans configuration) of the *CYP21A2* alleles identified. Family studies may be required in certain scenarios where phasing is required to determine the carrier status.

### Residual Risk Calculations

Carrier frequencies and detection rates for each ethnicity were calculated through the combination of internal curations of >30,000 variants and genomic frequency data from >138,000 individuals across seven ethnic groups in the gnomAD database. Additional variants in HGMD and novel deleterious variants were also incorporated into the calculation. Residual risk values are calculated using a Bayesian analysis combining the *a priori* risk of being a pathogenic mutation carrier (carrier frequency) and the detection rate. They are provided only as a guide for assessing approximate risk given a negative result, and values will vary based on the exact ethnic background of an individual. This report does not represent medical advice but should be interpreted by a genetic counselor, medical geneticist or physician skilled in genetic result interpretation and the relevant medical literature.

### Personalized Residual Risk Calculations

Agilent SureSelect™XT Low-Input technology was utilized in order to create whole-genome libraries for each patient sample. Libraries were then pooled and sequenced on the Illumina NovaSeq platform. Each sequencing lane was multiplexed to achieve 0.4-2x genome coverage, using paired-end 100 bp reads. The sequencing data underwent ancestral analysis using a customized, licensed bioinformatics algorithm that was validated in house. Identified sub-ethnic groupings were binned into one of 7 continental-level groups (African, East Asian, South Asian, Non-Finnish European, Finnish, Native American, and Ashkenazi Jewish) or, for those ethnicities that matched poorly to the continental-level groups, an 8<sup>th</sup> "unassigned" group, which were then used to select residual risk values for each gene. For individuals belonging to multiple high-level ethnic groupings, a weighting strategy was used to select the most appropriate residual risk. For genes that had insufficient data to calculate ethnic-specific residual risk values, or for sub-ethnic groupings that fell into the "unassigned" group, a "worldwide" residual risk was used. This "worldwide" residual risk was calculated using data from all available continental-level groups.

Several genes have multiple residual risks associated to reflect the likelihood of the tested individual being a carrier for different diseases that are attributed to non-overlapping pathogenic variants in that gene. When calculating the couples' combined reproductive risk, the highest residual risk for each patient was selected.

### Sanger Sequencing (Confirmation method) (Accuracy >99%)

Sanger sequencing, as indicated, was performed using BigDye Terminator chemistry with the ABI 3730 DNA analyzer with target specific amplicons. It also may be used to supplement specific guaranteed target regions that fail NGS sequencing due to poor quality or low depth of coverage (<20 reads) or as a confirmatory method for NGS positive results. False negative results may occur if rare variants interfere with amplification or annealing.

### Tay-Sachs Disease (TSD) Enzyme Analysis (Analytical Detection Rate ≥98%)

Hexosaminidase activity and Hex A% activity were measured by a standard heat-inactivation, fluorometric method using artificial 4-MU-β-N-acetyl glucosaminide (4-MUG) substrate. This assay is highly sensitive and accurate in detecting Tay-Sachs carriers and individuals affected with TSD. Normal ranges of Hex A% activity are 55.0-72.0 for white blood cells and 58.0-72.0 for plasma. It is estimated that less than 0.5% of Tay-Sachs carriers have non-carrier levels of percent Hex A activity, and therefore may not be identified by this assay. In addition, this assay may detect individuals that are carriers of or are affected with Sandhoff disease. False positive results may occur if benign variants, such as pseudodeficiency alleles, interfere with the enzymatic assay. False negative results may occur if both *HEXA* and *HEXB* pathogenic or pseudodeficiency variants are present in the same individual.

Please note that it is not possible to perform Tay-Sachs disease enzyme analysis on saliva samples, buccal swabs, tissue samples, semen samples, or on samples received as extracted DNA.

This test was developed, and its performance characteristics determined by Sema4 Opco, Inc. It has not been cleared or approved by the US Food and Drug Administration. FDA does not require this test to go through premarket FDA review. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. These analyses generally provide highly accurate information regarding the patient's carrier or affected status. Despite this high level of accuracy, it should be kept in mind that there are many potential sources of diagnostic error, including misidentification of samples, polymorphisms, or other rare genetic variants that interfere with analysis. Families should understand that rare diagnostic errors may occur for these reasons.

## SELECTED REFERENCES

### Carrier Screening

Grody W et al. ACMG position statement on prenatal/preconception expanded carrier screening. *Genet Med*. 2013 15:482-3.

**Fragile X syndrome:**

Chen L et al. An information-rich CGG repeat primed PCR that detects the full range of Fragile X expanded alleles and minimizes the need for Southern blot analysis. *J Mol Diag* 2010 12:589-600.

**Spinal Muscular Atrophy:**

Luo M et al. An Ashkenazi Jewish *SMN1* haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. *Genet Med*. 2014 16:149-56.

**Ashkenazi Jewish Disorders:**

Scott SA et al. Experience with carrier screening and prenatal diagnosis for sixteen Ashkenazi Jewish Genetic Diseases. *Hum. Mutat.* 2010 31:1-11.

Akler G et al. Towards a unified approach for comprehensive reproductive carrier screening in the Ashkenazi, Sephardi, and Mizrahi Jewish populations. *Mol Genet Genomic Med*. 2020 Feb 8(2):e1053.

**Duchenne Muscular Dystrophy:**

Flanigan KM et al. Mutational spectrum of *DMD* mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. *Hum Mutat.* 2009 30:1657-66.

**Variant Classification:**

Richards S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015 May;17(5):405-24

Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen) [published correction appears in *Genet Med*. 2021 Nov;23(11):2230]. *Genet Med*. 2020;22(2):245-257.

Additional disease-specific references available upon request.